Cellphire Inc., Rockville, Maryland, is awarded $20,000,000 for a cost-reimbursement, ceiling increase, in-scope modification (W81XWH-20-C-0030) to achieve a commercially viable cryopreserved platelet product for U.S. Food and Drug Administration licensure. The new contract ceiling is $44,909,972. Place of performance is Frederick, Maryland. The period of performance is Dec. 20, 2019, to July 31, 2028. The awardee will conduct all development, test and evaluation, manufacturing, and regulatory activities to achieve an FDA-licensed cryopreserved platelet product that is suitable for both civilian and military use. The awardee will explore development strategies that will enable rapid licensure and availability of CPP. Fiscal 2024 research, development, test, and evaluation funding is obligated at the time of award. The U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, is the contracting activity.
Contract Award: Cellphire Inc. (Rockville, Maryland) – $20,000,000
Defense Daily Staff
SHARE:
